Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) shares passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.99 and traded as low as $0.90. Clearside Biomedical shares last traded at $0.93, with a volume of 115,824 shares changing hands.
Analyst Ratings Changes
Several equities research analysts have issued reports on CLSD shares. StockNews.com upgraded shares of Clearside Biomedical from a "sell" rating to a "hold" rating in a research report on Thursday, December 12th. Chardan Capital restated a "buy" rating and issued a $6.00 price target on shares of Clearside Biomedical in a research note on Friday, November 15th. HC Wainwright reiterated a "buy" rating and set a $6.00 price objective on shares of Clearside Biomedical in a research report on Thursday, November 14th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $6.00 target price on shares of Clearside Biomedical in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.33.
Check Out Our Latest Research Report on Clearside Biomedical
Clearside Biomedical Stock Performance
The stock has a market capitalization of $70.53 million, a price-to-earnings ratio of -2.07 and a beta of 2.20. The company has a fifty day simple moving average of $0.99 and a two-hundred day simple moving average of $1.09.
Clearside Biomedical (NASDAQ:CLSD - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.04. The company had revenue of $1.04 million during the quarter, compared to analyst estimates of $0.25 million. During the same period last year, the firm earned ($0.15) EPS. As a group, equities analysts anticipate that Clearside Biomedical, Inc. will post -0.48 earnings per share for the current year.
Insider Activity at Clearside Biomedical
In other Clearside Biomedical news, insider Ngai Hang Victor Chong bought 36,500 shares of the stock in a transaction on Friday, November 1st. The stock was purchased at an average price of $1.00 per share, with a total value of $36,500.00. Following the completion of the purchase, the insider now owns 100,000 shares in the company, valued at $100,000. The trade was a 57.48 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 9.20% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Clearside Biomedical
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in shares of Clearside Biomedical by 8.8% during the third quarter. Geode Capital Management LLC now owns 731,386 shares of the company's stock valued at $929,000 after purchasing an additional 59,089 shares in the last quarter. Johnson & Johnson acquired a new stake in Clearside Biomedical in the third quarter valued at $105,000. XTX Topco Ltd raised its position in Clearside Biomedical by 172.2% during the 2nd quarter. XTX Topco Ltd now owns 54,313 shares of the company's stock worth $71,000 after purchasing an additional 34,359 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in Clearside Biomedical by 6.6% during the 2nd quarter. Renaissance Technologies LLC now owns 582,689 shares of the company's stock worth $757,000 after purchasing an additional 35,900 shares during the last quarter. 18.75% of the stock is owned by institutional investors.
Clearside Biomedical Company Profile
(
Get Free Report)
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Read More
Before you consider Clearside Biomedical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clearside Biomedical wasn't on the list.
While Clearside Biomedical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
